Molecularly targeted drugs for metastatic colorectal cancer - Wikidata - wikimedia - TriplyDB

Molecularly targeted drugs for metastatic colorectal cancer

Molecularly targeted drugs for metastatic colorectal cancer

http://www.wikidata.org/entity/Q26828735

about

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.FOXQ1 mediates the crosstalk between TGF-β and Wnt signaling pathways in the progression of colorectal cancer.Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer.Wnt-β-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer.Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism.Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.Construction of interference vector targeting Ep-CAM gene and its effects on colorectal cancer cell proliferation.The efficacy and safety of aflibercept and conbercept in diabetic macular edema Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding

P2860

Q28075557-7144B2C1-CC92-4E70-98EA-5FBFC7F12B85 Q28655505-FC39E9EA-17BE-4E71-9072-57C24E426D5F Q30490267-7653EEC1-196F-42C3-A9FD-E919BBE6F0BC Q33576659-9E7950BE-5C31-4FBA-BE44-AF34B92AE264 Q34278085-7C6A6DD4-6224-4A33-8451-340FC6146C12 Q34347975-F27EDDDE-F61D-4473-AB6F-3AE2606ED7DF Q35604265-372010AF-53AB-42BE-A0CA-4D0D2CE8AFA8 Q36160774-FFE19AE6-D392-4784-B2B8-55257D7DE119 Q36216202-A18478B0-F9F3-4269-8F2D-A662B4B519A5 Q36448079-72E23D30-14D7-416B-BF86-4C99DC7FC676 Q37544377-1A59E884-D0B9-4494-89CD-CE147E339E44 Q37700988-8C8ABFC9-5A6B-4451-908B-F80A1797C317 Q38885294-C4AF233A-22A7-4FDF-8EE0-B4B444BC1EC3 Q40954412-8E3ED7D7-1DEA-4882-A81B-37868ECEC99E Q58562047-F09A05C3-D42D-4609-A2DE-C7FFF282CE69 Q58567666-7756BEC6-D83F-4F1B-8C17-8494A70F18D1

P2860

Molecularly targeted drugs for metastatic colorectal cancer

http://www.wikidata.org/entity/Q26828735

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Molecularly targeted drugs for metastatic colorectal cancer

@ast

Molecularly targeted drugs for metastatic colorectal cancer

@en

Molecularly targeted drugs for metastatic colorectal cancer

@nl

type

label

Molecularly targeted drugs for metastatic colorectal cancer

@ast

Molecularly targeted drugs for metastatic colorectal cancer

@en

Molecularly targeted drugs for metastatic colorectal cancer

@nl

prefLabel

Molecularly targeted drugs for metastatic colorectal cancer

@ast

Molecularly targeted drugs for metastatic colorectal cancer

@en

Molecularly targeted drugs for metastatic colorectal cancer

@nl

P1433

Q26828735-BA1E5F10-E308-48A2-AFFA-32D5381BC6C8

P1476

Q26828735-23165475-FBDD-4640-B0D7-9FFE59BF31F7

P2093

Q26828735-2C08D8C5-E7D9-4ACB-A42F-45AEDEB87A08

Q26828735-820D26BD-3098-4E30-B046-610EA2C96911

Q26828735-91E2D97C-A0D5-4B63-A4DB-28ED4608B882

Q26828735-D123FF1F-A95A-4495-AC74-26E298387C1C

P275

Q26828735-3D8BC4D8-285B-409C-9059-9D9E4B7174FB

P2860

Q26828735-03CAFC89-0B4B-4762-A04E-1456F5A49A2B

Q26828735-08C6D44E-ECF8-4DEF-97C1-0DA8E8CB90DF

Q26828735-0CB4A62F-A905-4255-8E6D-547E13E386DD

Q26828735-0D85EF6F-856E-4928-BCA9-BD2AD520941D

Q26828735-158C25A4-5474-498C-A1EA-C09799823AF8

Q26828735-1618C232-7C71-42E4-80C5-AA8FF52B383E

Q26828735-17654B3E-5888-485F-B24F-5D14850542C2

Q26828735-21B82168-25F6-4D6D-8DB8-46FCAA4F1B99

Q26828735-242A655C-C9E3-4724-9C4F-5BC88E1AA361

Q26828735-2796C455-5CA4-4DC3-A5F8-D97282EBDE01

P304

Q26828735-C50AF1EB-0D56-4A4D-A3F5-EFA1B30B8BE5

P31

Q26828735-8E54EB23-2469-4BD9-98AF-9FAE475260BB

Q26828735-F694C7C7-F68B-4102-A811-289DEA0E6886

P3181

Q26828735-05717E6F-C42A-4A81-A241-E708CA42338E

P356

Q26828735-BE75C82E-6373-4F7B-AD37-5EF4C4C1A221

P407

Q26828735-E1A5A8E6-43DE-4067-BAEF-82ADC66069A0

P478

Q26828735-4CEF3FD3-6E95-47A0-9B64-189C023A7BCA

P5008

Q26828735-3CF63D74-793C-4E8C-A6DD-640226718D38

P577

Q26828735-46387AA9-D771-4212-A9DC-503426E29ECD

Q26828735-A08AFA95-9A6A-4FFC-88BA-607BD25D9D9B

P5875

Q26828735-0640ECDE-8E69-403D-A07E-72F19390C6AB

P698

Q26828735-59A0D67E-194C-459F-B7FC-ED491276C73C

P921

Q26828735-5C13102A-362F-4A93-B149-4F260AA391D2

Q26828735-F266DD80-7800-450C-9C00-48C83D10ACE0

P932

Q26828735-1B0F5026-AF1F-4F82-A170-F1C78A958557

P3181

P356

P1433

Drug Design, Development and Therapy

P1476

Molecularly targeted drugs for metastatic colorectal cancer

@en

P2093

Guo-qing CHEN

http://www.w3.org/2001/XMLSchema#string

Hua Yang

http://www.w3.org/2001/XMLSchema#string

Ying-dong CHENG

http://www.w3.org/2001/XMLSchema#string

Zhi-cao ZHANG

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy

Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases

Combining antiangiogenics to overcome resistance: rationale and clinical experience

Contemporary use of bevacizumab in ovarian cancer

Cetuximab for the treatment of colorectal cancer.

VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

Administration of anti-EGFR therapy: a practical review.

Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.

P304

1315-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3033538

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/DDDT.S52485

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258350429

http://www.w3.org/2001/XMLSchema#string

P698

24204124

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

colorectal neoplasm

P932

3817019

http://www.w3.org/2001/XMLSchema#string